These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30497501)

  • 1. GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy.
    Im JH; Kang KW; Kim SY; Kim YG; An YJ; Park S; Jeong BH; Choi SY; Lee JS; Kang KW
    J Exp Clin Cancer Res; 2018 Nov; 37(1):295. PubMed ID: 30497501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPR119: a promising target for nonalcoholic fatty liver disease.
    Yang JW; Kim HS; Im JH; Kim JW; Jun DW; Lim SC; Lee K; Choi JM; Kim SK; Kang KW
    FASEB J; 2016 Jan; 30(1):324-35. PubMed ID: 26399788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
    Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
    Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
    Nunez DJ; Bush MA; Collins DA; McMullen SL; Gillmor D; Apseloff G; Atiee G; Corsino L; Morrow L; Feldman PL
    PLoS One; 2014; 9(4):e92494. PubMed ID: 24699248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of TIGAR sensitizes the antitumor effect of physapubenolide through increasing intracellular ROS levels to trigger apoptosis and autophagosome formation in human breast carcinoma cells.
    Ma T; Zhang Y; Zhang C; Luo JG; Kong LY
    Biochem Pharmacol; 2017 Nov; 143():90-106. PubMed ID: 28774732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ICI 182,780, an ERα and ERβ antagonist, and G-1, a GPER agonist, on autophagy in breast cancer cells.
    Muler ML; Antunes F; Guarache GC; Oliveira RB; Ureshino RP; Bincoletto C; Pereira GJDS; Smaili SS
    Einstein (Sao Paulo); 2020; 18():eAO4560. PubMed ID: 32321078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
    Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells.
    Ning Y; O'Neill K; Lan H; Pang L; Shan LX; Hawes BE; Hedrick JA
    Br J Pharmacol; 2008 Dec; 155(7):1056-65. PubMed ID: 18724386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119.
    Engelstoft MS; Norn C; Hauge M; Holliday ND; Elster L; Lehmann J; Jones RM; Frimurer TM; Schwartz TW
    Br J Pharmacol; 2014 Dec; 171(24):5774-89. PubMed ID: 25117266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of autophagy inhibitor combined with EGFR inhibitor on triple-negative breast cancer MDA-MB-468 and MDA-MB-231 cells].
    Liu ZY; He KW; Song XG; Wang XZ; Zhuo PY; Wang XW; Ma QH; Huo ZJ; Yu ZY
    Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):417-24. PubMed ID: 27346398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms.
    Flock G; Holland D; Seino Y; Drucker DJ
    Endocrinology; 2011 Feb; 152(2):374-83. PubMed ID: 21068156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bidirectional GPR119 Agonism Requires Peptide YY and Glucose for Activity in Mouse and Human Colon Mucosa.
    Tough IR; Forbes S; Herzog H; Jones RM; Schwartz TW; Cox HM
    Endocrinology; 2018 Apr; 159(4):1704-1717. PubMed ID: 29471473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
    Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
    Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways.
    Lan H; Lin HV; Wang CF; Wright MJ; Xu S; Kang L; Juhl K; Hedrick JA; Kowalski TJ
    Br J Pharmacol; 2012 Apr; 165(8):2799-807. PubMed ID: 22029751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Cell Inactivation of
    Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ
    Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.